Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for BioScience Health Innovations (BHIC) over the last 5 years, with Q3 2025 value amounting to -$17814.0.

  • BioScience Health Innovations' Change in Accured Expenses fell 366280.0% to -$17814.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4186.0, marking a year-over-year increase of 6744.0%. This contributed to the annual value of $4543.0 for FY2024, which is 21331.03% up from last year.
  • Latest data reveals that BioScience Health Innovations reported Change in Accured Expenses of -$17814.0 as of Q3 2025, which was down 366280.0% from $3750.0 recorded in Q2 2025.
  • BioScience Health Innovations' Change in Accured Expenses' 5-year high stood at $14757.0 during Q1 2025, with a 5-year trough of -$17814.0 in Q3 2025.
  • Over the past 5 years, BioScience Health Innovations' median Change in Accured Expenses value was $562.5 (recorded in 2021), while the average stood at $709.0.
  • The largest annual percentage gain for BioScience Health Innovations' Change in Accured Expenses in the last 5 years was 347142.86% (2025), contrasted with its biggest fall of 366280.0% (2025).
  • Quarter analysis of 5 years shows BioScience Health Innovations' Change in Accured Expenses stood at $625.0 in 2021, then crashed by 135.36% to -$221.0 in 2022, then soared by 756.11% to $1450.0 in 2023, then soared by 140.9% to $3493.0 in 2024, then plummeted by 609.99% to -$17814.0 in 2025.
  • Its Change in Accured Expenses was -$17814.0 in Q3 2025, compared to $3750.0 in Q2 2025 and $14757.0 in Q1 2025.